Akcea and Ionis launch late-stage study ATTR cardiomyopathy study

Ionis Pharmaceuticals (NASDAQ:IONS) and majority-owned affiliate Akcea Therapeutics (NASDAQ:AKCA) initiate a Phase 3 clinical trial, CARDIO-TTRansform, evaluating cardiovascular (CV) outcomes in transthyretin-mediated amyloid cardiomyopathy (ATTR cardiomyopathy) patients receiving AKCEA-TTR-Lrx.

The primary endpoints of the 750-subject study are a composite of CV mortality and clinical events from baseline to week 120 and the change from baseline at week 61 in six-minute walk test distance.

The estimated primary completion date is January 2024.

https://seekingalpha.com/news/3530942-akcea-and-ionis-launch-late-stage-study-attr-cardiomyopathy-study